Artificial intelligence standardizing clinician-driven, evidence-based medicine

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

MENA-based healthcare organizations are creating fully connected digital ecosystems and shifting to value-based care. Because of this, Mazin Gadir of Alvarez & Marsal says basic EMRs are no longer enough for these health systems.

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.